Related Experiment Video
Updated: Jun 5, 2026
Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
New advances in molecular approaches to head and neck squamous cell carcinoma
Nivedita Sahu1, Jennifer Rubin Grandis
1Department of Otolaryngology, School of Medicine, University of Pittsburgh, Pennsylvania, USA.
Abstract:
Head and neck squamous cell cancer is the sixth most common cancer in the world. Despite advances in combined modality therapy, poor outcomes continue to be observed in the form of locoregional recurrence, metastasis, and development of second primary tumors. As tumors vary in their molecular and genetic etiology and because often there is already deregulation at the molecular level in otherwise histopathologically normal tissue, risk stratification using clinical and pathologic criteria alone has proved to be inadequate. In this article, the reader will gain an appreciation for the current advances in biomarker discovery using advanced technology and data interpretation in microarray analysis and proteomics. In addition, other molecular targets, aside from epidermal growth factor receptor, are discussed in the context of their promising role in predicting recurrence, response to therapy, survival, and overall prognosis.
Insights
Head and neck squamous cell cancer (HNSCC) requires advanced molecular biomarkers for accurate risk stratification. Current methods are insufficient, necessitating novel approaches for improved patient outcomes in HNSCC.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Head and neck squamous cell cancer (HNSCC) is a global health concern, ranking as the sixth most common malignancy worldwide.
- Despite therapeutic advancements, HNSCC outcomes remain poor due to high rates of recurrence, metastasis, and secondary tumors.
- Existing clinical and pathological criteria are inadequate for precise risk stratification due to tumor heterogeneity and molecular deregulation in seemingly normal tissues.
Purpose of the Study:
- To explore recent breakthroughs in biomarker discovery for HNSCC.
- To highlight the role of advanced technologies like microarray analysis and proteomics in interpreting complex molecular data.
- To discuss novel molecular targets beyond epidermal growth factor receptor (EGFR) for predicting HNSCC patient outcomes.
Main Methods:
- Review of current literature on biomarker discovery in HNSCC.
- Analysis of data interpretation techniques in microarray analysis and proteomics.
- Identification and discussion of emerging molecular targets and their clinical relevance.
Main Results:
- Advanced technologies offer enhanced capabilities for identifying predictive biomarkers in HNSCC.
- Proteomics and microarray analysis provide deeper insights into HNSCC molecular pathology.
- Several molecular targets show promise in predicting HNSCC recurrence, therapeutic response, and survival.
Conclusions:
- Biomarker discovery using advanced technologies is crucial for improving HNSCC risk stratification.
- Novel molecular targets hold significant potential for enhancing prognostic accuracy and guiding treatment decisions in HNSCC.
- Integrating molecular data with clinical information is essential for optimizing HNSCC patient management and improving survival rates.
